The combined data convinced the FDA that anifrolumab's effects warranted approval – a decision thought to reflect at least in part the pressing need for new treatment options for people with SLE.
Steroids can cause serious side effects with long-term use. The TULIP-1 data has now been published in The Lancet and shows that the BICLA response rate was 37% with anifrolumab and 27% with ...
Hosted on MSN28d
Anifrolumab Tied to Less Organ Damage for Patients With LupusTHURSDAY, Feb. 20, 2025 (HealthDay News) -- For patients with moderately to severely active systemic lupus erythematosus (SLE), anifrolumab is associated with less organ damage after 208 weeks ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback